FDA Issues Complete Response Letter to Saol Therapeutics for Pyruvate Dehydrogenase Complex Deficiency Treatment

The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Saol Therapeutics regarding its application for a treatment targeting pyruvate dehydrogenase complex deficiency (PDCD). The pharmaceutical company disclosed that addressing the concerns outlined in the CRL could require several years of additional work.

Saol Therapeutics did not provide specific details about the issues raised by the FDA but acknowledged that significant time and effort would be necessary to resolve them. PDCD is a rare metabolic disorder, and the company’s proposed treatment was under review as a potential therapeutic option. The FDA’s CRL indicates that the agency cannot approve the application in its current form, requiring further data or modifications before reconsideration.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 8, 2025

Author

Mark Chiang